PTC Therapeutics, Inc., a South Plainfield, NJ-based biopharmaceutical company has received a $5m Seeding Drug Discovery (SDD) Award from the Wellcome Trust.
The company intends to use the funding for the development of small-molecule drugs that target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative bacteria.
Led by President and CEO W. Peltz, Ph.D., PTC Therapeutics applies its expertise in RNA biology and drug development to pioneer novel oral treatments for patients living with serious and life-threatening conditions. Its internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology, and infectious diseases.
FinSMEs
23/12/2011
Related News
22/12/2009: PTC Therapeutics Raises 50M in Equity Financing